Quote of the Day Category

Gilead and the hedge fund managers

In: Quote of the Day

Activists Target Hedge Fund Managers Cashing In on Predatory Drug Pricing Schemes from Gilead Sciences Vocal New York, May 5, 2015 On the eve of Gilead Science’s annual shareholder meeting, activists criticized the pharmaceutical giant’s decision to price its Hepatitis C Virus (HCV) cure out of reach for millions of sick people by targeting three […]

  • Comments Off on Gilead and the hedge fund managers

HHS moving forward with Pioneer ACO model

In: Quote of the Day

Affordable Care Act payment model saves more than $384 million in two years, meets criteria for first-ever expansion HHS.gov, May 4, 2015 Today, an independent evaluation report released by the Department of Health and Human Services showed that an innovative payment model created as a pilot project by the Affordable Care Act generated substantial savings […]

  • Comments Off on HHS moving forward with Pioneer ACO model

Almost half of Obamacare exchanges face financial struggles in the future By Lena H. Sun and Niraj Chokshi The Washington Post, May 1, 2015 Nearly half of the 17 insurance marketplaces set up by the states and the District under President Obama’s health law are struggling financially, presenting state officials with an unexpected and serious […]

  • Comments Off on ACA exchanges and private insurance brokers struggle financially

Florida House Goes Home Early Over Medicaid Impasse By Lynn Hatter, WFSU Kaiser Health News, April 29, 2015 The Florida House – at odds with the state Senate over the expansion of Medicaid – abruptly ended its session three days early on Tuesday, leaving hundreds of bills unrelated to health care unfinished. The Republican-led state […]

  • Comments Off on The Florida House Speaker’s opposition to Medicaid

Blue Cross and Blue Shield Companies to Launch Retiree Health Insurance Exchange BlueCross BlueShield Association, April 24, 2015 Blue Cross and Blue Shield (BCBS) companies will launch a health insurance exchange this summer that will support employers’ efforts to help retirees transition from group health benefits to individual Medicare coverage that starts Jan. 1, 2016. […]

  • Comments Off on The BlueCross BlueShield Association is privatizing Medicare

Medicaid Rebates for Brand-Name Drugs Exceeded Part D Rebates by a Substantial Margin Department of Health and Human Services, Office of Inspector General, April 2015 Conclusion Drug rebates reduce the program costs of both Medicare Part D and Medicaid. Medicaid rebates are defined by statute and include additional rebates when prices for brand-name drugs increase […]

  • Comments Off on CMS passively rejects any government role in reducing Part D drug costs

Stuart Butler on Section 1332 waivers

In: Quote of the Day

Why Section 1332 Could Solve the Obamacare Impasse By Stuart Butler, PhD The JAMA Forum, April 28, 2015 Section 1332 of the ACA, known as “State Innovation Waivers,” allows states, starting in 2017, to apply to the federal government for 5-year renewable waivers from key provisions of the legislation. For instance, states could request changes […]

  • Comments Off on Stuart Butler on Section 1332 waivers

Pharmaceutical Companies Buy Rivals’ Drugs, Then Jack Up the Prices By Jonathan D. Rockoff and Ed Silverman The Wall Street Journal, April 26, 2015 On Feb. 10, Valeant Pharmaceuticals International Inc. bought the rights to a pair of life-saving heart drugs. The same day, their list prices rose by 525% and 212%. Neither of the […]

  • Comments Off on Pharmaceutical firms contribute to wealth inequity

The Demise of Vermont’s Single-Payer Plan By John E. McDonough, Dr.P.H., M.P.A. The New England Journal of Medicine, April 23, 2015 On December 17, 2014, Vermont Governor Peter Shumlin publicly ended his administration’s 4-year initiative to develop, enact, and implement a single-payer health care system in his state. In reality, the Vermont plan was abandoned […]

  • Comments Off on John McDonough on Vermont’s single payer lesson

Are we seeing the end of low priced generics?

In: Quote of the Day

Teva Offers to Buy Mylan in $40.1B Cash-and-Stock Deal By Linda A. Johnson, AP ABC News, April 21, 2015 Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan’s cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by […]

  • Comments Off on Are we seeing the end of low priced generics?

About this blog

Physicians for a National Health Program's blog serves to facilitate communication among physicians and the public. The views presented on this blog are those of the individual authors and do not necessarily represent the views of PNHP.

News from activists

PNHP Chapters and Activists are invited to post news of their recent speaking engagements, events, Congressional visits and other activities on PNHP’s blog in the “News from Activists” section.